Bone Biologics - BBLGW STOCK NEWS

Bone Biologics (Nasdaq: BBLG), a developer of orthobiologic products for spine fusion markets, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, in New York City. Jeffrey Frelick, the company's CEO, will deliver a virtual presentation, which will be accessible online starting September 9th at 7:00 a.m. Eastern time.

The presentation will remain available on the company's website for a time. Bone Biologics' management team will also be available for virtual one-on-one meetings throughout the conference. Institutional investors and industry professionals can choose to attend the conference either virtually or in-person at the Lotte New York Palace Hotel.

Bone Biologics (Nasdaq: BBLG), a developer of orthobiologic products for spine fusion markets, has announced a $2.1 million gross proceeds from the exercise of warrants. The company entered into a definitive agreement for the exercise of existing warrants to purchase 781,251 shares of common stock at $2.43 per share. In exchange, Bone Biologics will issue new unregistered warrants to purchase up to 1,562,502 shares of common stock at $2.00 per share.

The new warrants will have varying terms: half with a five-year term and half with an eighteen-month term. H.C. Wainwright & Co. is acting as the exclusive placement agent. The offering is expected to close around August 2, 2024. Bone Biologics plans to use the net proceeds to fund clinical trials, maintain and extend its patent portfolio, and for working capital and general corporate purposes.

Bone Biologics (Nasdaq: BBLG) has commenced the first treatments in its pilot clinical study evaluating the NB1 bone graft device for spine fusion in patients with degenerative disc disease (DDD). The study, involving 30 patients, aims to assess the safety, effectiveness, fusion success, pain relief, functional improvement, and adverse events of NB1. The first two patients were treated in Australia. The U.S. FDA has reviewed and agreed upon the study's design, which could support a pivotal U.S. trial. CEO Jeffrey Frelick highlighted NB1's potential to address a $3 billion global spine fusion market.

Bone Biologics Corporation (BBLG) closes public offering, raising $2.0 million for clinical trials and patent portfolio.

Bone Biologics Corporation (BBLG) announces the pricing of a public offering of 781,251 shares of common stock and warrants at $2.56 per share, aiming to raise capital for its orthobiologic products in spine fusion markets.

Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) appoints Robert E. Gagnon, a seasoned finance and business operations professional, to its board of directors. With over 20 years of experience in leading global finance operations and serving in executive roles at various life sciences companies, Mr. Gagnon's appointment is expected to bring valuable expertise in clinical stage companies, capital raising, and commercial organizations to support Bone Biologics' growth and its pilot study with NB-1.

Bone Biologics Corporation (BBLG) has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. The company's common stock will continue to be listed on The Nasdaq Capital Market, but will remain under Nasdaq’s discretionary panel monitor until June 28, 2024. Bone Biologics failed to meet the closing bid price of $1.00 for 30 consecutive business days but regained compliance by maintaining a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days, as of January 4, 2024.

Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) announces a planned 1-for-8 reverse stock split of its shares of common stock, effective December 20, 2023. Stockholders approved the split at a special meeting on December 12, 2023. The reverse stock split aims to adjust the stock price and number of outstanding shares, with the new CUSIP number of the common stock being 098070501.